Alnylam Pharmaceuticals, Inc.

URI: https://gptkb.org/entity/Alnylam_Pharmaceuticals,_Inc.
GPTKB entity
Statements (37)
Predicate Object
gptkbp:instanceOf gptkb:biotechnology
gptkbp:CEO gptkb:John_Maraganore
gptkb:Yvonne_Greenstreet
gptkbp:collaboratesWith gptkb:Sanofi
gptkb:Novartis
gptkb:Regeneron_Pharmaceuticals
gptkb:Vir_Biotechnology
gptkbp:firstFDAApproval gptkb:Onpattro_(2018)
gptkbp:focus RNA interference therapeutics
gptkbp:foundedYear 2002
gptkbp:founder gptkb:David_Bartel
gptkb:John_Maraganore
gptkb:Phil_Sharp
gptkb:Paul_Schimmel
gptkb:Phillip_Zamore
gptkb:Thomas_Tuschl
gptkbp:headquartersLocation gptkb:Cambridge,_Massachusetts,_United_States
https://www.w3.org/2000/01/rdf-schema#label Alnylam Pharmaceuticals, Inc.
gptkbp:industry gptkb:biotechnology
gptkbp:marketCap over $20 billion (2023)
gptkbp:notableProduct gptkb:Amvuttra
gptkb:Givlaari
gptkb:Onpattro
gptkb:Oxlumo
gptkbp:numberOfEmployees ~2000 (2023)
gptkbp:patent RNAi therapeutics
gptkbp:platform RNAi (RNA interference)
gptkbp:publiclyTraded true
gptkbp:stockExchange gptkb:NASDAQ
gptkbp:stockSymbol gptkb:ALNY
gptkbp:therapeuticArea genetic diseases
rare diseases
cardiometabolic diseases
hepatic infectious diseases
gptkbp:website https://www.alnylam.com/
gptkbp:bfsParent gptkb:NASDAQ:_ALNY
gptkbp:bfsLayer 7